ATNM
Actinium Pharmaceuticals Inc
$
1.670
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.690
Open
1.520
VWAP
1.60
Vol
377.13K
Mkt Cap
52.10M
Low
1.500
Amount
604.53K
EV/EBITDA(TTM)
--
Total Shares
29.78M
EV
-17.58M
EV/OCF(TTM)
--
P/S(TTM)
--
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The Company develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).
Show More
3 Analyst Rating
259.28% Upside
Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
259.28% Upside
Current: 1.670
Low
4.00
Averages
6.00
High
9.00
259.28% Upside
Current: 1.670
Low
4.00
Averages
6.00
High
9.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-04-28
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-04-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-27
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-25
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$4
2025-03-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$4
2025-03-18
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Actinium Pharmaceuticals Inc (ATNM.A) is -1.31, compared to its 5-year average forward P/E of -5.56. For a more detailed relative valuation and DCF analysis to assess Actinium Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.56
Current PE
-1.31
Overvalued PE
-2.79
Undervalued PE
-8.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.26
Current EV/EBITDA
0.31
Overvalued EV/EBITDA
-0.31
Undervalued EV/EBITDA
-4.20
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
223.68
Current PS
0.00
Overvalued PS
658.78
Undervalued PS
-211.43
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+73.37%
-16.64M
Operating Profit
FY2025Q1
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q1
YoY :
+64.52%
-0.51
EPS - Diluted
FY2025Q1
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATNM News & Events
Events Timeline
2025-05-06 (ET)
2025-05-06
08:47:08
Actinium enrolls first patient on the trial studying Iomab-ACT
2025-04-28 (ET)
2025-04-28
08:35:57
Actinium Pharmaceuticals' ATNM-400 shows efficacy in prostate cancer study
2025-04-28
08:05:39
Actinium's Actimab-A shows antileukemic activity in AML models
Sign Up For More Events
Sign Up For More Events
News
7.0
05-16PRnewswireActinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
7.0
05-16GlobenewswireInvestors who lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact Levi & Korsinsky about pending Class Action - ATNM
7.0
05-14NewsfilterKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
Sign Up For More News
People Also Watch
WMT
Walmart Inc
98.240
USD
+1.96%
AAPL
Apple Inc
211.260
USD
-0.09%
TSLA
Tesla Inc
349.980
USD
+2.09%
META
Meta Platforms Inc
640.340
USD
-0.55%
MSFT
Microsoft Corp
454.270
USD
+0.25%
ORCL
Oracle Corp
160.490
USD
+0.68%
AVGO
Broadcom Inc
228.610
USD
-1.73%
XOM
Exxon Mobil Corp
108.190
USD
-0.36%
AMZN
Amazon.com Inc
205.590
USD
+0.20%
NVDA
NVIDIA Corp
135.400
USD
+0.42%
FAQ
What is Actinium Pharmaceuticals Inc (ATNM) stock price today?
The current price of ATNM is 1.67 USD — it has increased 9.15 % in the last trading day.
What is Actinium Pharmaceuticals Inc (ATNM)'s business?
What is the price predicton of ATNM Stock?
What is Actinium Pharmaceuticals Inc (ATNM)'s revenue for the last quarter?
What is Actinium Pharmaceuticals Inc (ATNM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Actinium Pharmaceuticals Inc (ATNM)'s fundamentals?
How many employees does Actinium Pharmaceuticals Inc (ATNM). have?